Latest Breaking News On - Nurron pharmaceuticals inc - Page 1 : vimarsana.com

WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to announce the appointment of Dr. Almira Chabi, MD, EGMP to its Board of Directors, effective November 24, 2023. Dr. Chabi.

United statesDeog joong kimAlmira chabiPrnewswire hanall biopharmaWharton business school executive management programMichaelj fox foundationNeuroscience ophthalmology clinical research groupHanall pharmaceutical internationalNurron pharmaceuticals incCalifornia institute for regenerative medicineResearch funding grants working groupNurron pharmaceuticalsAll biopharmaChief medical officerChief development officerMedical research funding grants working group